Amer M. Zeidan

1.2k total citations · 1 hit paper
21 papers, 729 citations indexed

About

Amer M. Zeidan is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Amer M. Zeidan has authored 21 papers receiving a total of 729 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 5 papers in Genetics and 4 papers in Molecular Biology. Recurrent topics in Amer M. Zeidan's work include Acute Myeloid Leukemia Research (19 papers), Hematopoietic Stem Cell Transplantation (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). Amer M. Zeidan is often cited by papers focused on Acute Myeloid Leukemia Research (19 papers), Hematopoietic Stem Cell Transplantation (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). Amer M. Zeidan collaborates with scholars based in United States, France and Italy. Amer M. Zeidan's co-authors include Rory M. Shallis, Xiaomei Ma, Rong Wang, Amy J. Davidoff, Jan Philipp Bewersdorf, Maximilian Stahl, Alexander B. Pine, Kishan Patel, Nikolai A. Podoltsev and Scott F. Huntington and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Nature Reviews Clinical Oncology.

In The Last Decade

Amer M. Zeidan

18 papers receiving 717 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges

2019 579 citations Rory M. Shallis, Rong Wang et al. Blood Reviews profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amer M. Zeidan United States	7	493	378	160	126	109	21	729
Daniel H. Wiseman United Kingdom	15	337 0.7×	529 1.4×	96 0.6×	104 0.8×	134 1.2×	46	854
Paola Panetta Italy	14	573 1.2×	440 1.2×	145 0.9×	162 1.3×	59 0.5×	27	858
Eli Estey United States	8	782 1.6×	480 1.3×	136 0.8×	247 2.0×	89 0.8×	10	996
Yu Jing China	15	443 0.9×	301 0.8×	92 0.6×	127 1.0×	78 0.7×	74	667
F. Messa Italy	8	453 0.9×	366 1.0×	91 0.6×	208 1.7×	71 0.7×	15	724
Isabelle Luquet France	13	499 1.0×	195 0.5×	88 0.6×	159 1.3×	41 0.4×	45	636
Jennifer N. Saultz United States	9	263 0.5×	247 0.7×	101 0.6×	69 0.5×	145 1.3×	31	506
Anna Szmigielska‐Kapłon Poland	16	215 0.4×	198 0.5×	151 0.9×	187 1.5×	103 0.9×	55	570
Mohammad Azab United States	10	309 0.6×	367 1.0×	61 0.4×	87 0.7×	38 0.3×	19	543
A. Mario Marcondes United States	14	256 0.5×	203 0.5×	126 0.8×	79 0.6×	167 1.5×	23	564

Countries citing papers authored by Amer M. Zeidan

Since Specialization

Citations

This map shows the geographic impact of Amer M. Zeidan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amer M. Zeidan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amer M. Zeidan more than expected).

Fields of papers citing papers by Amer M. Zeidan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amer M. Zeidan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amer M. Zeidan. The network helps show where Amer M. Zeidan may publish in the future.

Co-authorship network of co-authors of Amer M. Zeidan

This figure shows the co-authorship network connecting the top 25 collaborators of Amer M. Zeidan. A scholar is included among the top collaborators of Amer M. Zeidan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amer M. Zeidan. Amer M. Zeidan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chaer, Firas El, Jan Philipp Bewersdorf, Maximilian Stahl, & Amer M. Zeidan. (2025). The global epidemiology of acute myeloid leukaemia. Nature Reviews Clinical Oncology. 23(2). 107–120.

Fiel, M. Isabel, et al.. (2024). Drug Development for Hematological Cancer Targets Using Asclepius. Blood. 144(Supplement 1). 7464–7464.

Bewersdorf, Jan Philipp, et al.. (2024). Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome. Leukemia & lymphoma. 65(11). 1541–1551. 1 indexed citations

Garcia‐Manero, Guillermo, Matteo Giovanni Della Porta, Valeria Santini, et al.. (2024). Multilineage and Safety Results From the COMMANDS Trial in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS). Clinical Lymphoma Myeloma & Leukemia. 24. S192–S192. 1 indexed citations

Bewersdorf, Jan Philipp, et al.. (2024). Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them. Cancers. 16(23). 4092–4092.

Zeidan, Amer M., et al.. (2024). Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets. SHILAP Revista de lepidopterología. 3. 1 indexed citations

Zeidan, Amer M., Mikkael A. Sekeres, Hanny Al‐Samkari, et al.. (2024). A Phase 2B, Open-Label Multicenter Study of Tebapivat (AG-946), a Potent Pyruvate Kinase Activator, in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes. Blood. 144(Supplement 1). 6708–6708. 2 indexed citations

Bewersdorf, Jan Philipp, et al.. (2024). Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions. Expert Review of Anticancer Therapy. 24(11). 1131–1146. 1 indexed citations

Bewersdorf, Jan Philipp, Kishan Patel, George Goshua, et al.. (2022). Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood. 139(11). 1766–1770. 4 indexed citations

10.

Shallis, Rory M., Alexa J. Siddon, & Amer M. Zeidan. (2021). Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis. Current Hematologic Malignancy Reports. 16(3). 276–285. 1 indexed citations

11.

Shallis, Rory M. & Amer M. Zeidan. (2021). Management of the Older Patient with Myelodysplastic Syndrome. Drugs & Aging. 38(9). 751–767. 7 indexed citations

12.

Bewersdorf, Jan Philipp, Andrew S. Kowalski, Steven D. Gore, et al.. (2020). High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. Leukemia & lymphoma. 62(5). 1195–1202. 4 indexed citations

13.

Bewersdorf, Jan Philipp, Rory M. Shallis, & Amer M. Zeidan. (2020). Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways. Blood Reviews. 45. 100709–100709. 27 indexed citations

14.

Shallis, Rory M., Rong Wang, Amy J. Davidoff, Xiaomei Ma, & Amer M. Zeidan. (2019). Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Reviews. 36. 70–87. 579 indexed citations breakdown →

15.

Shallis, Rory M. & Amer M. Zeidan. (2019). Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a “catch-all” term?. Best Practice & Research Clinical Haematology. 33(2). 101132–101132. 5 indexed citations

16.

Bewersdorf, Jan Philipp, Rory M. Shallis, Maximilian Stahl, & Amer M. Zeidan. (2019). Epigenetic therapy combinations in acute myeloid leukemia: what are the options?. Therapeutic Advances in Hematology. 10. 152108474–152108474. 63 indexed citations

17.

Pine, Alexander B., et al.. (2019). Getting personal with myelodysplastic syndromes: is now the right time?. Expert Review of Hematology. 12(4). 215–224. 9 indexed citations

18.

Shallis, Rory M., et al.. (2018). Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Review of Hematology. 11(9). 715–726. 13 indexed citations

19.

Shallis, Rory M. & Amer M. Zeidan. (2018). More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. SHILAP Revista de lepidopterología. 18(1). 4–4. 6 indexed citations

20.

Shallis, Rory M., et al.. (2018). Conviction in the face of affliction: a case series of Jehovah’s Witnesses with myeloid malignancies. Annals of Hematology. 97(11). 2245–2248. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact